Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
0.5015
-0.0395 (-7.30%)
At close: Aug 14, 2026, 4:00 PM EDT
0.6259
+0.1244 (24.81%)
After-hours: Aug 14, 2026, 7:59 PM EDT
Skye Bioscience Employees
Skye Bioscience had 2 employees as of March 31, 2026. The number of employees decreased by 10 or -83.33% since the number was last reported on December 31, 2025.
Employees
2
Change
-10
Growth
-83.33%
Revenue / Employee
n/a
Profits / Employee
-$25,246,289
Market Cap
17.62M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 2 | -10 | -83.33% |
| Dec 31, 2025 | 12 | -4 | -25.00% |
| Dec 31, 2024 | 16 | 5 | 45.45% |
| Dec 31, 2023 | 11 | 0 | - |
| Dec 31, 2022 | 11 | 2 | 22.22% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 115 |
| Palatin Technologies | 29 |
| Citius Pharmaceuticals | 23 |
| Werewolf Therapeutics | 14 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
| Tempest Therapeutics | 5 |
SKYE News
- 1 day ago - Skye Bioscience Quarterly report: Q2 2026 - Filings
- 2 days ago - Skye Bioscience Transcript: M&A announcement - Transcripts
- 2 days ago - Skye Bioscience Press release: M&A announcement - Filings
- 2 days ago - Skye Bioscience Slides: M&A announcement - Filings
- 2 days ago - Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings - GlobeNewsWire
- 2 days ago - Skye Bioscience Proxy statement: Proxy filing - Filings
- 2 months ago - Skye Bioscience Transcript: AGM 2026 - Transcripts
- 3 months ago - Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 - GlobeNewsWire